Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

Inclusion Criteria: * Male or female who is at least 18 years of age or older. * A clinical diagnosis of facial rosacea. * A Clinician Erythema Assessment (CEA) score of ≥3 at Screening and at Baseline (prior to study drug application). * A Patient Self Assessment (PSA) score of ≥3 at Screening and at Baseline (prior to study drug application). Exclusion Criteria: * Particular forms of rosacea (rosacea conglobata, rosacea fulminans, isolated rhinophyma, isolated pustulosis of the chin) or other concomitant facial dermatoses that are similar to rosacea such as peri-oral dermatitis, demodicidosis, facial keratosis pilaris, seborrheic dermatitis, acute lupus erythematosus, or actinic telangiectasia. * Current diagnosis of Raynaud's syndrome, thromboangiitis obliterans, orthostatic hypotension, severe cardiovascular disease, cerebral or coronary insufficiency, renal or hepatic impairment, scleroderma, Sjögren's syndrome, or depression. * Previous refractive eye surgery such as photorefractive keratectomy (PRK), laser-assisted sub-epithelial keratectomy (LASEK), or laser-assisted in situ keratomileusis (LASIK). * Current treatment with monoamine oxidase (MAO) inhibitors. * Current treatment with barbiturates, opiates, sedatives, systemic anesthetics, or alpha-agonists. * Less than 3 months stable dose treatment with tricyclic anti-depressants, cardiac glycosides, beta blockers or other antihypertensive agents.